The optimal management of left ventricular thrombus (LVT) remains controversial. Despite
decreasing incidence with improvements in early percutaneous revascularization, LVT
is estimated to occur after 6.3% of ST elevation myocardial infarctions.
1
Because a key tenet of Virchow's triad for thrombosis includes blood stasis, nonischemic
cardiomyopathy remains another, although less frequent, cause of LVT. Variability
in etiology may add to the elusiveness of determining an optimal therapy. Nevertheless,
LVT remains a pertinent pathology for patients and clinicians.- Bulluck H
- Chan MHH
- Paradies V
- Yellon RL
- Ho HH
- Chan MY
- Chin CWL
- Tan JW
- Hausenloy DJ.
Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance
in acute ST-segment elevation myocardial infarction treated by primary percutaneous
coronary intervention: a meta-analysis.
J Cardiovasc Magn Reson. 2018; 20: 72
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a meta-analysis.J Cardiovasc Magn Reson. 2018; 20: 72
- Edoxaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2013; 369: 2093-2104
- Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med. 2009; 361 ([published correction appears in N Engl J Med 2010;363:1877]): 1139-1151
- Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med. 2011; 365: 883-891
- Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.N Engl J Med. 2012; 366: 1287-1297
- Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59–7939 in Patients With Acute Symptomatic deep-vein thrombosis) study.Circulation. 2007; 116: 180-187
- Dabigatran versus warfarin in patients with mechanical heart valves.N Engl J Med. 2013; 369: 1206-1214
- Management of left ventricular thrombi with direct oral anticoagulants: retrospective comparative study with vitamin K antagonists.Clin Drug Investig. 2020; 40: 343-353
- Treatment of left ventricular thrombus with direct oral anticoagulants: a retrospective observational study.Am J Med. 2020; 133: 1488-1491
- Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus.ESC Heart Fail. 2020; 7: 2032-2041
- The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction.Eur Heart J Cardiovasc Pharmacother. 2021; 7: 398-404
- Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi.JAMA Cardiol. 2020; 5: 685-692
- Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus.J Thromb Thrombolysis. 2021; 52: 517-522
- Direct oral anticoagulant use in left ventricular thrombus.Thromb J. 2020; 18: 29
- Comparative study of oral anticoagulation in left ventricular thrombi (No-LVT Trial).J Am Coll Cardiol. 2021; 77: 1590-1592
- Left ventricular thrombus following acute myocardial infarction: JACC state-of-the-art review.J Am Coll Cardiol. 2022; 79: 1010-1022
Seiler T, Vasiliauskaite E, Grüter D, Young M, Attinger-Toller A, Madanchi M, Cioffi GM, Tersalvi G, Müller G, Stämpfli SF, de Boeck B, Suter Y, Nossen J, Toggweiler S, Wuillemin WA, Cuculi F, Kobza R, Bossard M. Direct oral anticoagulants versus vitamin K antagonists for the treatment of left ventricular Thrombi-Insights from a Swiss multicenter registry. Am J Cardiol. 2023.
Article info
Publication history
Published online: March 14, 2023
Received:
February 9,
2023
Publication stage
In Press Journal Pre-ProofFootnotes
Funding: none.
See page 1 for disclosure information.
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
